Business Description
Kronos Bio Inc
NAICS : 541714
SIC : 2833
1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402
Description
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.06 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -127.9 | |||||
| 3-Year EPS without NRI Growth Rate | -104.7 | |||||
| 3-Year FCF Growth Rate | -103.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.11 | |||||
| 9-Day RSI | 47.61 | |||||
| 14-Day RSI | 50.8 | |||||
| 6-1 Month Momentum % | -41.1 | |||||
| 12-1 Month Momentum % | -77.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.19 | |||||
| Quick Ratio | 18.19 | |||||
| Cash Ratio | 17.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -41.77 | |||||
| ROA % | -37.25 | |||||
| ROIC % | -266.69 | |||||
| ROC (Joel Greenblatt) % | -389.72 | |||||
| ROCE % | -38.52 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.86 | |||||
| Price-to-Tangible-Book | 0.92 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-Forward-EBIT | -0.41 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-FCF | -0.36 | |||||
| Price-to-Net-Current-Asset-Value | 1.19 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | -904.26 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:KRON
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.98 | ||
| Beta | 0 | ||
| Volatility % | 60.9 | ||
| 14-Day RSI | 50.8 | ||
| 14-Day ATR ($) | 0.403698 | ||
| 20-Day SMA ($) | 4.95275 | ||
| 12-1 Month Momentum % | -77.83 | ||
| 52-Week Range ($) | 2.96 - 25.01 | ||
| Shares Outstanding (Mil) | 56.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kronos Bio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||